C4 Therapeutics, Inc. (CCCC): Shareholders' Equity
$256.59M
As of 2025-12-31
$247.26M
As of 2026-06-30
-3.9%
3-year compound annual growth
-1.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $256.59M | +18.8% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $215.99M | -12.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $246.11M | -14.9% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $289.23M | -25.8% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $389.61M | +38.8% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $280.79M | n/m | 2022-02-24, Balance as of period end |
| 2019-12-31 | -$111.96M | n/a | 2022-02-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $256.59M | +18.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $186.29M | +741.1% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $92.25M | +63.6% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.58B | +89.0% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$14.27M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $196.08M | -34.6% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $27.29M | -79.7% |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$207.78M | n/m |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.47M | n/m |
Compare CCCC, XFOR, DTIL, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗